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Summary 
The injection of 2.0 mg chymopapain into the adolescent rabbit knee causes severe loss of articular cartilage 
proteoglycans (PG). Although chondrocytes attempt o restore lost PG, failure to repair ensues. Pure chondroitin 
4,6-sulfate (Condrosulf ~', IBSA Lugano, Switzerland) has been used in c]inical studies of human osteoarthritis (OA) 
as a slow-acting drug for OA (SYSADOA). Using our model of articular cartilage injury, we examined the effects 
of oral and intramuscular administration of Condrosulf" after chymopapain-induced cartilage injury. In this study, 
animals received an injection of 2.0 mg chymopapain (Chymodiactin H, Boots Pharmaceuticals) into the left knee 
and were sacrificed after 84 days. The contralateral right knee served as a noninjected control. Some animals 
received oral Condrosulf ~'while others received intramuscular injections of CondrosulP ~. Serum keratan sulfate 
(KS) levels were monitored to ensure degradation of the cartilage PG. Those animals not exhibiting at least a 
100% increase of serum KS following chymopapain i jection were excluded from the study. At sacrifice, cartilage 
PG contents were markedly reduced in animals receiving an injection of 2.0 mg chymopapain with no further 
treatment. In contrast, oral administration of Condrosulf" beginning 11 days prior to chymopapain i jury resulted 
in significantly higher (P--0.0036) cartilage PG contents. Intramuscular administration of Condrosulf 'i resulted in 
higher, but less significantly so (P=0.0457), cartilage PG contents. These results suggest hat daily Condrosulf" 
treatment prior to and continuing after chymopapain jury may have a protective ffect on the damaged cartilage, 
allowing it to continue to re-synthesize matrix PG after the treatment is discontinued. 
Key words: Chondroitin 4,6-sulfate, Chymopapain model, New Zealand White rabbits, Serum keratan sulfate. 
Introduction 
DISEASES of the synovial  jo int  are a leading cause 
of disabi l i ty worldwide result ing in signif icant 
social and economic burdens [1]. In joint diseases 
character ized by progressive loss of art icular  
cart i lage, e.g. osteoarthr i t is  (OA), the destruct ion 
of the art icu lat ing surfaces is usual ly most 
pronounced in areas which are maximal ly  loaded, 
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a l though the loaded tissue is bel ieved to be capable 
of making an at tempt at repair;  for example, the 
early stages of OA are accompanied by a marked 
increase in the synthesis of matr ix  const i tuents 
[2 8], bel ieved to reflect an at tempt  by the cells to 
repair  the cart i lage damage. However,  reparat ive  
attempts are usual ly not successful. 
Art icular  cart i lage lines the ends of long bones 
in synovial  joints. It  contains re lat ively few cells 
embedded in a large extracel lu lar  matr ix  r ich in 
hydrophi l ic  proteoglycans (PG), f iber-forming col- 
lagens (types II, VI, IX and XI) and other matr ix  
components  which contr ibute to its st ructura l  
integrity [9, 10]. The PG form aggregates of very 
large size, at t ract  water  in the t issue and then 
swell to occupy very large domains. The volume 
occupied by these PG molecules is restr icted by the 
col lagenous fibri l lar network  in which they are 
immobil ized [11]. Cross- l inking of col lagen mole- 
cules and fibrils gives the network  its tensi le 
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strength [10]. The arrangement of these extracellu- 
lar macromolecules, aswell as the water entrapped 
in the tissue, gives cartilage its ability to undergo 
rapid reversible deformation during loading. Loss 
of the deformable PG and/or damage to the 
cross-linked fibrillar network have been identified 
as early changes in experimental and human OA 
[12]. 
The mechanisms at play in the repair of 
articular cartilage following injury are poorly 
understood. The success of the repair process is 
dependent upon several factors such as age, 
magnitude of the cartilage injury, location of the 
injury and choice of therapeutic intervention 
[13]. The experimental depletion of cartilage 
matrix components by the application of matrix- 
degrading enzymes has led to important obser- 
vations regarding the ability of the chondrocytes 
to replenish and/or repair lost matrix com- 
ponents. Intravenous injection of papain, a 
proteolytic enzyme, in the rabbit has been used 
to demonstrate that cartilage in the ear, trachea 
and ribs is able to replenish the PG degraded by 
the enzyme [14, 15]. These attempts appear to be 
more substantial in younger, skeletally imma- 
ture, than older animals. Subsequent studies 
have suggested that the loading forces placed 
upon the injured cartilage may affect adversely 
the repair processes [14, 16, 17]. Thus, one or 
more injections of relatively high concentrations 
(minimum of 9 mg/joint) of crude papain into the 
rabbit knee joint were shown to result in 
progressive loss of cartilage in maximally loaded 
areas and in exposure of the underlying subchon- 
dral bone. However, in spite of massive damage 
to the articular cartilage and surrounding joint 
structures, attempts by the cartilage to repair 
matrix loss were noted [14, 16, 17]. 
Treatment of joint diseases where loss of 
articular cartilage occurs includes the use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) 
for relief of pain and inflammation. Chronic 
NSAID therapy is associated with several serious 
side-effects, including gastric ulceration, hemor- 
rhage and perforation of the gastrointestinal 
tract [18, 19]. Due to these side-effects, new issues 
in the pharmacological management of OA 
disease have been explored and new ground 
therapies have been investigated. This has led to 
the use of slow-acting drugs for the treatment of 
OA (SADOA), an approach officially accepted by 
the WHO/ILAR Task Force in 1994 [20]. Thus, it 
is now possible to distinguish between symp- 
tomatic slow-acting drugs for the treatment of 
OA (SYSADOA) and disease-modifying OA drugs 
(DMOAD). SYSADOA are characterized by a 
slow onset of action in humans, beginning 
approximately 6 weeks after the start of therapy; 
they aid in alleviating pain and functional 
symptoms of OA disease. These effects can 
continue for a significant period of time after 
cessation of treatment. Chondroitin 4,6-sulfate 
belongs to the SYSADOA, as do diacerhein, 
hyaluronan and glucosamine sulfate. 
DMOAD drugs do not exist at the moment; 
they would be SYSADOA having the additional 
potential to influence the natural course of OA 
disease and to modify the course of OA struc- 
turally. 
Recently, we developed a rabbit model of 
articular cartilage repair to study the response of 
chondrocytes in vivo to proteolytic degradation 
of matrix constituents. In our model, the chon- 
drocytes are able to repair the damage caused by 
an intra-articular injection of a small dose of 
chymopapain (0.2 mg), and the articular surface 
maintains both its integrity and functionality for 
at least 6 months. In contrast, the injection of a 
higher dose (2.0 mg) reproducibly causes irrevers- 
ible damage which leads to severe progressive 
destruction of articular cartilage in load-bearing 
regions [21 23]. The percentage of PG remaining 
in the cartilage matrix after the injection is 
similar for the two doses of chymopapain (CP), 
suggesting that the inability to repair the injured 
articular surface after the injection of 2.0 mg CP 
is not related exclusively to the pronounced 
decrease in the concentration of resilient PG 
within the tissue. 
Using the CP model of articular cartilage 
degradation and repair, the authors set up a 
preliminary study to examine the effects of a 
symptomatic slow-acting drug for OA (chon- 
droitin 4,6-sulfate; Condrosulf ~) which is in use 
for human OA in Europe [24, 25]. That pilot 
study was conducted on 10 rabbits injected with 
2.0 mg CP into the left knee joint and treated 
with 20 mg/kg/day of 4,6-CS (Condrosulf '~) given 
intramuscularly from day 10 before the injection 
of CP until 21 days after the injection. These 
animals were compared with 11 rabbits which did 
not receive CondrosulP ~treatment in conjunction 
with the CP injection. There were no significant 
differences between both groups at sacrifice (day 
21) with respect to serum and synovial fluid 
keratan sulfate (KS), urinary collagen cross-links 
(Pyr and D-Pyr), cartilage tissue total sulfated 
PGs and histologic appearances. A third group of 
three rabbits receiving Condrosulf" treatment 
and a CP injury was permitted to live after 
discontinuing Condrosulf ~ treatment until sac- 
rifice, 84 days after the CP injection. Impor- 
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tantly, this group had a significantly higher 
cartilage PG content and less synovial inflam- 
mation, chondrocyte death and cluster forma- 
tion. 
This study reports the results of an expansion of 
the pilot study where groups of animals receiving 
a CP injury were treated with oral or intramuscu- 
lar 4,6-CS for a time (11 days before through 21 
days after) with Condrosulg ") after which the drug 
was discontinued. The animals then were not 
sacrificed until 84 days after the chymopapain 
injection. 
Mater ia l s  and  Methods  
ANIMALS AND IN JECT ION PROCEDURES 
Thirty-six male New Zealand White adolescent 
rabbits (3.(~3.5 kg) were used. Each animal (n = 36) 
received an intra-articular injection of 2.0mg 
chymopapain (CP) into the left knee. Twelve 
animals (group CP) received no further treatment 
after the chymopapain i jection. Of the remaining 
animals, 12 animals received daily oral 
administration (80 mg/day) of Condrosulf ~ (group 
oral 4,6-CS) or daily intramuscular injection 
(80rag/day) of Condrosulf ~ (group IM 4,6-CS). 
Condrosulf ~ treatment began 11 days prior to 
chymopapain i jection and continued for 21 days. 
Thereafter, Condrosulf ~ administration was 
discontinued. Care was taken to administer 
Condrosulf ~ at the same time each day. The 
contralateral right knee served as a noninjected 
control in all cases. All animals were sacrificed 84 
days after the chymopapain injection. 
For the intra-articular chymopapain injection, 
animals were anesthetized by an intramuscular 
injection of ketamine/acepromazine (1.0 cc/1.5 kg 
body weight) of a mixture of ketamine (35 mg/cc) 
and xylazine (5mg/cc) after which the left 
knee was shaved and washed with 70% alcohol. 
A sterile solution of 2.0mg chymopapain 
activated by sodium L-cysteinate hydrochloride 
(Chymodiactin | a gift from Boots Phar- 
maceuticals) in 0.5 ml of sterile water was injected 
by aseptically passing a 25-gauge needle attached 
to a tuberculin syringe through the joint capsule 
lateral to the patellar ligament. Each allotment of 
enzyme was accompanied by a certification of 
enzymatic activity if used within a certain period 
of time (1 mg chymopapain = 500 picoKatal units). 
In all instances, the enzyme was used well within 
the allotted time period. All animals tolerated the 
injection procedure well with no significant 
adverse reactions. Animals were inspected aily by 
the staff of the Comparative Research Center 
(Rush-Presbyterian-St. Luke's Medical Center). 
The study was accepted by the Animal 
Institutional Ethical Committee. 
Condrosulf ~ is a complex of pure chondroitin 
4,6-sulfate xtracted from shark skeleton and used 
for oral administration in humans. Condrosul~ R
was suspended in sterile water, and a 0.5 ml volume 
was placed at the base of the tongue using a curved 
4-inch feeding needle attached to a tuberculin 
syringe. Intramuscular injections of Condrosul~ R
were performed using a 25-gauge needle attached 
to a tuberculin syringe. An injection of 0.5 ml into 
alternating muscle sites in the shoulder and hip 
was used. 
ELISA FOR THE QUANTIF ICAT ION OF SERUM KERATAN 
SULFATE (KS) 
The main purpose of measuring serum antigenic 
KS was to ensure that degradation of articular 
cartilage PG did indeed occur in all animals 
injected with the enzyme. Serum KS epitope was 
quantified by a previously described ELISA [26] 
modified to permit accurate quantification of a 
highly sulfated KS epitope in rabbit serum [21]. In 
order to establish a normal baseline for the serum 
level of antigenic KS, serum samples were 
obtained prior to the start of the experiment (day 
-11). Samples were taken again just prior to 
chymopapain i jection (day 0), 24 h after injection 
(day 1) and at sacrifice (84 days). The anti-KS 
monoclonal antibody 1/20/5-D-4 used in this study 
has been well characterized and shown to be 
specific for a sulfated carbohydrate moiety on KS 
chains [26]. All results were calculated in terms of 
equivalents of an international standard of KS 
purified from human costal cartilage (a gift from 
Drs M. B. Mathews and A. L. Horwitz, University 
of Chicago, Chicago, IL). For each animal, the 
change in the serum level of antigenic KS at 
different times was calculated by deducting the 
pre-injection baseline level from each 
post-injection level; the change was expressed as 
ng antigenic KS per ml of serum. 
ROUTINE L IGHT MICROSCOPIC  ANALYS IS  
The knee joints were opened immediately at 
sacrifice and examined for gross changes. The 
patellae were removed rapidly and fixed in 10% 
neutral buffered formalin containing 0.5% 
cetylpyridinium chloride (Sigma, St Louis, MO, 
USA). Samples then were decalcified in aqueous 
formic acid/sodium citrate (22/10%) after which 
they were processed for paraffin embedding. 
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Full-thickness sections (8 pm) through the 
articular cartilage and underlying subchondral 
bone were obtained and placed on glass slides 
coated with Vectabond (Vector Laboratories Inc., 
Burlingame, CA). Sections were stained for routine 
histologic and histochemical analysis with 
safranin O to exhibit matrix PG [27] or with 
hematoxylin and eosin. Sections of patellae from 
experimental and control knees from the same 
animals were processed and stained concurrently 
to control for any variations in uptake of the stain. 
HISTOLOGIC  ANALYS IS  
Controls 
The articular cartilage from all noninjected 
knees exhibited a smooth articular surface, normal 
cellularity and intense staining of matrix PGs with 
safranin O in the three groups. Similarly, the 
synovial membrane was normal, consisting of a 
lining cell layer of 2 4 cells thick and a highly 
vascularized, loose areolar subsynovium. 
CARTILAGE PG CONTENT 
At sacrifice, a full-thickness portion of articular 
cartilage (2• discs) from the habitually 
loaded region of the medial femoral condyle was 
removed and stored at -70~ for subsequent 
biochemical analysis. Cartilage samples were 
placed in two changes of acetone for 48 h and dried 
in vacuum at 80~ until a constant weight was 
obtained. The dried cartilage then was weighed, 
placed in test tubes and digested with papain 
(27 pg/ml) overnight at 60~ The digestion was 
terminated by boiling the test tubes for 5 min. 
Aliquots were removed for subsequent analysis by 
the dimethylmethylene blue colorimetric assay 
(DMMB) [28] as described in modified form [29, 30]. 
Thus, cartilage PG content was expressed as pg 
PG/mg cartilage dry weight. 
Resu l ts  
GROSS EXAMINATION 
All animals were maintained in good general 
health; they ate and drank a normal amount and 
had no noticeable differences in physical activity 
when compared to similar animals involved in 
other studies but maintained in the same room. 
The animals experienced a normal age-related 
weight gain during the study. All joints which 
received intra-articular chymopapain were swollen 
slightly and had effusions for 2-4 days after the 
injection which were resolved by 7 days. In 
general, articular cartilage in all noninjected 
knees was grossly normal. However, cartilage 
discoloration was noted in all animals receiving 
chymopapain jections and no further treatment. 
In addition, small surface disruptions were noted 
occasionally in the knees of these animals. 
Cartilage discoloration was noted also in animals 
receiving chymopapain and chondroitin 
4,6-sulfate. However, no other gross changes were 
noted in these joints. 
Chymopapain i jury with no treatment 
All animals receiving 2.0 mg chymopapain and 
no further treatment exhibited a severe loss of 
safranin O staining in the uncalcified layer of 
articular cartilage. Surface defects, cell loss 
(30-50%) and disruption of the normal cellular 
architecture were observed. Loss of cells increased 
with the severity of surface disruptions. 
Osteophytic proliferations were noted at the joint 
margins in a few animals (n = 4). Brood clusters 
were seen in nearly every animal. The 
synovial membrane was normal in all injected 
knees. 
Chymopapain i jury with oral 4,6-CS treatment 
Increased safranin O staining was noted 
throughout the cartilage in animals receiving a 
single injection of chymopapain and oral 4,6-CS. In 
addition, cell loss and brood clusters were reduced 
and cellular architecture was returned to normal. 
No surface defects or osteophytes were seem in any 
animal receiving a single injection of chymopapain 
and oral 4,6-CS treatment. The synovial membrane 
was normal in all animals. 
Chymopapain injury with intramuscular 4,6-CS 
treatment 
The previously observed improvements in 
cartilage histology were less pronounced in 
animals receiving chymopapain and intra- 
muscular 4,6-CS. Focal areas of pronounced loss of 
safranin O staining and cells were seen in six 
animals of this group. Cell architecture was 
disrupted in these areas as well. A focal surface 
defect was seen in one animal and osteophytes 
were seen in two animals receiving a single 
injection of chymopapain and intra-muscular 
4,6-CS treatment. The synovial membrane was 
normal in all animals of this group. 
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SERUM LEVELS OF KS  (FIG. 1) 
Pre- inject ion levels var ied from rabbit  to rabbi t  
(mean + S.D. = 57 + 20 ng/ml). The purpose of the 
serum KS measurement  was to document the 
damage from intra-art icu lar  chymopapain  by 
moni tor ing the elevat ion in serum KS which 
typical ly occurs 24h after the injection. Serum 
samples were obta ined from animals at days -11,  
0 and +1. Serum samples obtained at days -11  
and 0 were pr ior to chymopapain  injection 
and were thus considered basel ine levels. 
Accordingly,  serum KS levels at days -11  and 0 
were within normal  l imits for rabbi t  serum. 
In sharp contrast,  a dramat ic  increase in 
concentrat ion of serum KS was noted in all 
animals  24 h after the chymopapain  injection. The 
differences between basel ine and peak values in 
these groups were highly signif icant (P=0.001). 
Serum levels of ant igenic KS returned within 
normal  l imits by sacrif ice (CP = 14 _+ 4 ng/ml; oral 
4,6-CS -- 25 +_ 9 ng/ml; IM 4,6-CS = 24 • 32 ng/ml). 
Important ly ,  serum KS levels did not rise in 
response to Condrosu l f  a administrat ion only. 
BIOCHEMICAL ANALYS IS  
The total  sulfated PGs in art icular  cart i lage, as 
determined by the DMMB assay, gave the 
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FIG. 1. Changes in serum keratan sulfate (KS) from 
pre-injection levels at various times following intra-ar- 
ticular injection of 2 mg of chymopapain (CP) (n = 36). 
The results are expressed as mean • S.D. change in 
rabbits injected with CP and not treated, injected with 
CP and treated with oral chondroitin 4,6-sulfate (Oral 
4,6-CS) and rabbits injected with CP and treated with 
intramuscular chondroitin 4,6-sulfate (IM 4,6-CS). 
*P = 0.001. 
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FIG. 2. Changes in weight-bearing femoral condyle 
articular cartilage proteoglycan (PG) content at sac- 
rifice (day 84) following the injection of 2 mg chymopa- 
pain (CP) into the rabbit knee joint (n = 36). The results 
are expressed as mean i S.D. absolute changes in PG 
content for both left injected and right control articular 
cartilage for rabbits injected with CP and untreated, 
injected with CP and treated with oral chondroitin 
4,6-sulfate (Oral 4,6-CS) and rabbits injected with CP and 
treated with intramuscular chondroitin 4,6-sulfate 
(IM 4,6-CS). 
fol lowing results. Eighty-four days fol lowing 
intra-art icu lar  inject ion of 2.0 mg chymopapain  
into the left knee joint, the cart i lage PG content 
(Fig. 2) was highly reduced in the CP-only animal 
(P = 0.0005), whereas it was less reduced in 
the rabbits  t reated with in t ramuscu lar  (P = 0.003) 
or oral Condrosulg ~ (P=0.044). When results 
were expressed as a percentage of var iat ion of 
the contro latera l  knee (Fig. 3), cart i lage PG 
contents were signif icantly h igher in animals 
t reated with oral Condrosu l f f  (81 + 12%; 
P = 0.0036) or in t ramuscu lar  Condrosul f  '~ 
(76 + 14%; P=0.0457). 
Discuss ion  
The present invest igat ion was under taken in 
order to assess the effects of Condrosul f f ,  
composed of chondroit in  4,6-sulfate xtracted from 
the shark and regular ly  registered and used in 
Europe as an SYSADOA. (For more details on its 
cl inical use, see L. Bucsi et al. and D. Uebelhart  
et al. in this issue.) Regarding Condrosu l f  '~, there 
is strong evidence that  oral administrat ion of 
exogenous chondroit in 4,6-sulfate is effective in 
al leviat ing the inf lammatory and algofunct ional  
status of OA. Recent studies have shown that  it is 
as efficient as diclofenac sodium in pat ients 
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suffering from knee OA [25] but it does have a 
delayed therapeutic action which is in agreement 
with the concept of action of SYSADOA [31]. Our 
study confirmed that the chymopapain-induced 
acute cartilage degradation model developed in 
the rabbit could be used to test the ability of a 
pharmacologic compound to modulate the 
deleterious effects reproducibly observed in this 
model with the higher dose of chymopapain 
(2.0 mg). 
The data from the serum levels of KS are in close 
agreement with previously published papers 
showing that the ELISA-inhibition assay for KS 
was able to monitor the appearance in serum of 
KS-bearing fragments released from articular 
cartilage locally following chemonucleolysis 
induced by the injection of CP into a single knee 
joint in the rabbit [21], and in human [32] or canine 
[33] intervertebral discs. Interestingly, CP 
injection into a single knee joint induced a 
dramatic, sharp increase in serum KS levels which 
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FIG. 3. Changes in weight-bearing femoral condyle 
articular cartilage proteoglycan (PG) content at sac- 
rifice (day 84) following the injection of 2 mg chymopa- 
pain (CP) into the rabbit knee joint (n = 36). The results 
are expressed as mean _+ S.D. A% changes in PG content 
of controlateral rticular cartilage for rabbits injected 
with CP and not treated, injected with CP and treated 
with oral chondroitin 4,6-sulfate (Oral 4,6-CS) and 
rabbits injected with CP and treated with intramuscular 
chondroitin 4,6-sulfate (IM 4,6-CS). 
peaked at 24 h for all three groups of rabbits. This 
response appears to be a direct consequence of the 
intra-articular injection of CP and reflects the 
acute loss of PG from a single knee joint. It also 
provides evidence that PG fragments diffusing out 
of articular cartilage following enzymatic 
degradation appear in the blood as antigenic KS 
fragments [34] within a short period of time and 
can be measured at very high levels 24 h only after 
CP injection. 
At the time of sacrifice, the weight-bearing 
articular cartilage from the left CP-injected 
femoral condyles presented with a 33% decrease in 
PG content as compared to the right noninjected 
knee joint in the CP group (P = 0.0005). In the 
rabbits treated with oral chondroitin 4,6-sulfate, 
this reduction was only 19%, at the limit of 
significance (P= 0.044), whereas it was 21% in the 
rabbits treated with intramuscular injection of 
chondroitin 4,6-sulfate (P= 0.003). Expressed as a 
percentage of difference with the controlateral 
knee, there was no significant difference between 
either oral or intramuscular injection of 
chondroitin 4,6-sulfate-treated rabbits, whereas 
untreated CP rabbits did present with a highly 
significant difference when compared to both oral 
(P=0.0036) and intramuscular injection of 
chondroitin 4,6-sulfate (P= 0.0457) groups. 
These results could reflect some protective ffect 
of exogenous chondroitin 4,6-sulfate (Condrosulf ii)
administered both orally and intramuscularly in a 
rabbit model of acute articular cartilage 
degradation i duced by the injection of a high dose 
of CP into a single knee joint. Based upon previous 
findings regarding the CP model of acute articular 
cartilage degradation and repair in the rabbit, it 
appears most likely that the protective ffect of 
exogenous chondroitin 4,6-sulfate is linked to a 
direct or indirect effect on the PG of the 
extracellular matrix of articular cartilage. 
Nevertheless, as urinary excretion of pyridinium 
cross-links of collagen does increase after CP 
injection [35] and major alterations of the spatial 
orientation of the collagen network of articular 
cartilage do occur [36] as a consequence of CP 
injection, some involvment of the underlying 
collagenous matrix of articular cartilage cannot be 
totally excluded in the positive response to 
exogenous chondroitin 4,6-sulfate administration. 
The positive outcome of exogenous oral 
or intramuscular chondroitin 4,6-sulfate 
(Condrosulf") treatment in young rabbits injected 
intra-articularly with a high dose of CP, and the 
significant reduction in weight-bearing articular 
cartilage PG content loss, is certainly a very 
important finding which supports the contention 
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that  some SYSADOA such as chondroit in 
4,6-sulfate also could have disease- or 
structure-modify ing properties. Fur ther  studies 
are needed to confirm these effects, but this could 
obviously have important  cl inical consequences. 
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